#South Korea #Seoul #oncology #Clinical Trials #ImmunoForge

ImmunoForge to Present Innovative Oncology Therapies at BIO-Europe 2026

ImmunoForge Co., Ltd., a pioneering biopharmaceutical firm based in Korea, is gearing up to participate in the prestigious BIO-Europe 2026 event, taking place in Cologne, Germany, from November 9 to 11, 2026. This event is crucial for the company as it aims to solidify partnerships and expand its licensing opportunities in the realm of innovative treatments for rare and complex diseases.

The company, recognized for its clinical-stage developments, will leverage this international platform to engage with prominent leaders in the pharmaceutical sector. Attendees can expect in-depth discussions during one-on-one partnering sessions where ImmunoForge plans to showcase its cutting-edge drug delivery technologies and promising clinical pipelines. The firm is particularly keen on advancing its Licensing-Out (L/O) discussions and co-development initiatives for its key oncology projects.

Proprietary Platforms Focus

ImmunoForge has developed two notable platform technologies that serve as the backbone of its therapeutic innovations:

1. ELP (Elastin-Like Polypeptide) Platform: This versatile technology is designed to enhance drug delivery through a biopolymer approach, which prolongs the half-life of medications by as much as 200 times. The elasticity enabled by the ELP platform allows for sustained drug release without the adverse effects typically caused by high initial concentrations, ensuring a smoother therapeutic experience for patients. The platform is also designed for seamless integration with various substances, including peptides and proteins, enabling increased flexibility in administration schedules and significantly reduced production costs.

2. LMT (Leptin Receptor-Mediated Transcytosis) Platform: This groundbreaking technology aims to improve drug delivery specifically to the central nervous system (CNS) while minimizing peripheral wastage. By targeting the Leptin receptor, which is known for its selective affinity for brain tissues, the LMT platform enhances the effectiveness of treatments intended for CNS disorders. This includes preclinical successes in delivering large protein payloads and lipid nanoparticles directly to critical brain areas, such as the hypothalamus.

These platforms promise to empower the development of the company's lead clinical-stage oncology initiatives, which include:

Lead Clinical Pipelines

1. KF1601: A next-generation tyrosine kinase inhibitor designed specifically to combat drug-resistant Chronic Myeloid Leukemia (CML), particularly targeting the challenging ABL1 T315I mutation. Early studies reveal that KF1601 boasts superior selectivity and safety compared to current third-line treatments, reducing the risk of serious side effects. Co-development efforts are ongoing with a leading Korean pharmaceutical firm, with plans for domestic Phase 1 trials and discussions around global licensing partnerships.

2. PF1801: This advanced biological candidate utilizes the ELP platform to deliver a GLP-1-ELP fusion targeted at muscle disorders such as Dermatomyositis and Polymyositis. Currently advancing through Phase 2 trials, PF1801 has received Orphan Drug Designation by the FDA, positioning it as a pivotal therapy for these debilitating conditions.

3. PF1804: Another significant initiative focusing on Duchenne Muscular Dystrophy (DMD), this fusion protein activates the VPAC2 receptor to potentially mitigate cardiomyopathy related to the condition. PF1804 has also garnered FDA Orphan Drug Designation and is on track for Phase 2 trials, offering potential collaborators in the biopharma sector a low-risk investment opportunity with high-value assets.

Strategic Partnerships Ahead

The participation at BIO-Europe 2026 is an integral part of ImmunoForge’s strategy to forge new connections and expand its business horizons. According to Co-CEOs Sung-Min Ahn and Ki-Ho Chang, the event presents an excellent opportunity to explore and maximize the therapeutic potential of their assets within the global market.

ImmunoForge’s innovative approaches, alongside its commitment to addressing unmet medical needs, set the stage for potentially transformative partnerships in the biopharmaceutical ecosystem. As the company prepares for this major conference, its focus remains clear: to advance the frontiers of therapy for rare diseases and oncology, ensuring that patients receive revolutionary treatments that improve their quality of life.